曾昭冲,男,主任医师,教授,现任复旦大学中山医院放疗科主任,1962年9月出生,博士研究生导师,2001年7月开始主持中山医院放射治疗科工作至今。
1986年福建医科大学毕业。1989年考取我国肿瘤学家汤钊猷院士的硕士研究生,在中山医院肝癌研究所从事肝癌的导向内放疗临床工作, 这项工作在1996年荣获卫生部科技成果三等奖(第三完成者)。2003年获首届上海市医学科技奖3等奖,2005年荣获上海市第6届临床医疗成果2等奖,2006年获教育部科技成果一等奖,均为第一完成者。2008年获得国家科学技术进步2等奖(第三完成者)。作为第一作者或通讯作者在国外具有高影响因子的SCI医学期刊发表论著20余篇,这些论著在肝癌放疗领域得到国内外同行的广泛引用。1994年-1996年、1999年两度赴美国学习,共计3年,在美国放射治疗最高研究机构RTOG(全美放射治疗协作组)主席Curran医生,和著名放射生物学家、国际放射研究学会主席Iliakis教授的共同指导下,学习放射生物学、内外放疗实验和临床工作。回国后,致力于肝癌的放射治疗研究,论证肝癌属于放射敏感肿瘤,开创性地开展肝癌患者淋巴结转移、门脉/下腔静脉癌栓、肾上腺转移的放射治疗,由此推动人们对肝癌放射治疗的重新认识,这些论文在国际著名的放射治疗专业杂志《国际放射肿瘤学??生物学?物理学》、《癌症杂志》、《欧洲核医学杂志》、《美国临床肿瘤杂志》上发表。被《Cancer》、《International Journal of Radiation Oncology, Biology, Physics》、《American Journal of Clinical Oncology》等多家美国著名的肿瘤杂志邀请为审稿人,负责肝癌方面的评审。2001年被RTOG主席Curran医生和放射生物学家Iliakis教授共同邀请为Thomas Jefferson大学医院放射肿瘤科客座教授。美国放射肿瘤学会(ASTRO)会员,中国抗癌协会临床肿瘤协作委员会委员、上海市放疗学会委员。作为第一作者在国外具有高影响因子的SCI医学期刊发表论著13篇,这些论著在肝癌放疗领域得到国内外同行的广泛引用。发表论著:(仅限于英文SCI论文)。
1. Zeng ZC, Zhang SM, Tang ZY, et al. Caffeine enhanced radiation-induced apoptosis in heptocellular carcinoma cell line. Cancer Clin Res (Peer-review).
2. Zeng ZC, Tang ZY, et al. Consideration of the role of radiotherapy for unresectable intrahepatic cholangiocarcinoma? — a retrospective analysis of 75 patients. Cancer J 2006;14(2):113-122
3. Zeng ZC, Tang ZY, et al. Consideration of the role of radiotherapy for lymph node metastases in patients with HCC ─ A retrospective analysis for prognostic factors from 125 patients. Int J Radiation Oncology Boil Phys 2005:63(4):1067-1076
4. Zeng ZC, Tang ZY, et al. Radiation therapy for adrenal gland metastases from hepatocellular carcinoma. Jpn J Clin Oncol 2005;35(2):61-67
5. Zeng ZC, Fan J, et al: A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus. Int J Radiation Oncology Boil Phys 2005 ;61(2):432-443
6. Zeng ZC, Tang ZY, et al: A comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinoma. Cancer J 2004;10:307-316
7. Zeng ZC, Tang ZY, et al: Radiation therapy for the locoregional lymph node metastases from hepatocellular carcinoma, phase I clinical trial. Hepato-Gastroenterology2004;51:201-207
8. Zeng ZC, Tang ZY, et al: Comparison between radioimmunotherapy and external beam radiation therapy for patients with hepatocellular carcinoma. Eur J Nucl Med 2002;29:1657-68
9. Zeng ZC, Jiang GL, et al: DNA-PKcs subunits in radiosensitization by hyperthermia on hepatocellular carcinoma Hep G2 cell line. World J Gastroenterol 2002;8:797-803
10. Zeng ZC, Tang ZY, Wu ZQ, et al: Phase I clinical trial of oral Futulon and combined hepatic arterial chemoembolization and radiotherapy in unresectable primary liver cancers, including clinicopathological study. Am J Clinical Oncol 2000;23(5): 449-454
11. Zeng ZC, Tang ZY, Liu KD, et al: Improved long-term survival for unresectable hepatocellular carcinoma (HCC) with a combination of surgery and intrahepatic arterial infusion of 131I-anti-HCC mAb. Phase I/II clinical trials. J Cancer Res Clin Oncol 1998;124(5):275-280
12. Zeng ZC, Tang ZY, Liu KD, et al: Observation of changes of peripheral T lymphocyte subsets by flow cytometry in patients with liver cancer treated with radioimmunotherapy. Nucl Med Comm. 1995;16:378-385
13. Zeng ZC, Tang ZY, Xie H, et al: Human anti-(Murine Ig) antibody responses in patients with hepatocellular carcinoma receiving intrahepatic arterial 131I-Hepama-1 mAb-Preliminary results and discussion. Cancer Immunology Immunotherapy 1994;39:332-336
14. Zeng ZC, Tang ZY. Changes of serum alpha fetoprotein before and after radioimmunotherapy in patients with hepatocellular carcinoma. Chin J Cancer Res [English] 1994;6:83-90
15. Zeng ZC, Tang ZY, Xie H, et al: Radioimmunotherapy for unresectable hepatocellular carcinoma using 131I-Hepama-1 mAb: preliminary results. J Cancer Res Clin Oncol 1993;119:257-259
16. Geng CX, Zeng ZC, et al: Docetaxel inhibits SMMC-7721 human hepatocellular carcinoma cells growth and induces apoptosis. World J Gastroenterol 2003;9:696-700
17. Wang H, Zeng ZC, Bui TA, et al. Efficient rejoining of radiation-induced DNA double-strand breaks in vertebrate cells deficient in genes of the RAD52 epistasis group. Oncogene. 2001;20(18):2212-24
18. Wang H, Zeng ZC, Perrault AR, et al. Genetic evidence for the involvement of DNA ligase IV in the DNA-PK-dependent pathway of non-homologous end joining in mammalian cells. Nucleic Acids Res. 2001;29(8):1653-60
19. Wang HC, Zeng ZC, Bui TA, et al: Nonhomologous End-Joining of Ionizing Radiation-induced DNA Double-Stranded Breaks in Human Tumor Cells Deficient in BRCA1 or BRCA2. Cancer Res 2001 ;61:270-277
20. Cheong N, Zeng ZC, Iliakis G. Evidence for factors modulating radiation-induce G2-delay: potential application as radioprotectors. Physica Medica 2001;17(s):205-209
21. Asaad NA, Zeng ZC, Iliakis G, et al: Homologous recombination as a potential target for caffeine radiosensitization in mammalian cells: reduced caffeine radiosensitization in XRCC2 and XRCC3 mutants. Oncogene 2000;19:5788-800
22. Steven JD, Zeng ZC, Iliakis G, et al: DNA-dependent protein kinase stimulates an independently active, nonhomologous, end-joining apparatus. Cancer Res 2000;60:1245-53
23. Hu B, Zhou XY, Wang X, Zeng ZC, Iliakis G, Wang Y. The radioresistance to killing of a1-5 cells derives from activation of the chk1 pathway. J Biol Chem. 2001;276(21):17693-8
查看医生完整介绍
擅长
胸腹部肿瘤的放射治疗及综合治疗,特别是肝癌、肺癌等。
简介
我的团队
*医生信息来自医院官网公示信息或医生本人提供,平台受限于更新时效,可能出现信息更新不及时的情况
信息纠错
收起
已开通服务
曾昭冲的出诊时间
查看完整出诊信息- 上海中山医院 放疗科
-
05/22 周三 下午
高级专家门诊
-
05/29 周三 下午
高级专家门诊
该科室暂无出诊信息
曾昭冲的诊后评价 共25个
查看全部评价
肝癌 (8)
食道癌 (2)
胰腺癌 (2)
宫颈癌 (2)
胆道肿瘤 (1)
直肠癌 (1)
肺癌 (1)
小细胞肺癌 (1)
胆管癌 (1)
乳腺癌 (1)
纵隔肿瘤 (1)
椎管内肿瘤 (1)
放疗 (1)
收起
曾昭冲的科普专区 共9篇
进入医生的科普号-
发表于2013-09-125475人已读
-
发表于2013-01-056516人已读
-
发表于2013-01-056779人已读2条评价
-
发表于2013-01-054711人已读1条评价
-
发表于2013-01-055141人已读4条评价
曾昭冲的问诊记录 共人次
查看全部问诊以下是为您精选的问诊内容,供您参考